2019-01-23 sec.gov - Exhibit 99.1 Bellerophon Therapeutics, Inc. Bellerophon Therapeutics, Inc. Common Stock (BLPH) News ... 10/12. Provided by GlobeNewswire Nov 15, 2021 5:30 AM PST. BELLEROPHON THERAPEUTICS, INC. : BLPH Stock Price ... BLPH - Stock quote for BELLEROPHON THERAPEUTICS, INC ... - MSN About Us | Bellerophon Therapeutics Analysts Are Bullish on Top Healthcare Stocks: Bellerophon ... WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Thursday reported a loss of $8 million in its fourth quarter. Average Volume 93,595 shs. WARREN, N.J. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing. Two of the company's product candidates are based on its proprietary pulsatile nitric. BLPH Stock News - Fidelity The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Its. BLPH | Bellerophon Therapeutics Inc. Stock Price & News - WSJ BLPH | Complete Bellerophon Therapeutics Inc. stock news by MarketWatch. Hedge Funds Are Coming Back To Bellerophon Therapeutics, Inc. (BLPH) A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that. Disease Overview Interstitial lung disease (ILD) is a general category that includes many different lung conditions. WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on . In May, the FDA accepted Bellerophon's. WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Monday reported a loss of $4.6 million in its third quarter. See the full list of Bellerophon Therapeutics competitors, plus revenue, employees, and funding info on Owler, the world's largest community-based business insights platform. by Zacks Equity Research Published on November 05,2020. Nachrichten zur Aktie Bellerophon Therapeutics Inc Registered Shs | A2PZZR | BLPH | US0787713009 Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. Bellerophon Therapeutics (NASDAQ:BLPH): Q3 GAAP EPS of -$0.49 beats by $0.14. Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. This is a 41.67 percent increase over losses of $ (0.84) per share from the same period last year. As of September 30, 2021, the Company had cash and cash equivalents of $28.7 million, compared to $47.6 million at December 31, 2020. CMTX - Thu Mar 11, 7:30AM CST. View detailed BLPH description & address. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. investchronicle 6/23/2021. Bellerophon Therapeutics: Q3 Earnings Snapshot Automated Insights Nov 15, 2021 0 WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Monday reported a loss of $4.6 million in its third. Bellerophon Therapeutics announced the appointment of Naseem Amin, M.D., as chairman of its board of Directors, effective immediately. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. Bellerophon Therapeutics, Hampton, New Jersey. Earnings for Bellerophon Therapeutics are expected to decrease in the coming year, from ($2.05) to ($2.21) per share. Share . Bellerophon Therapeutics Inc. (BLPH) is set for a tempting yields with an average volume of 61.50K. Bellerophon Therapeutics (BLPH) stock price, charts, trades & the US's most popular discussion forums. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its REBUILD Phase 3 registrational clinical study evaluating INOpulse ®, a . No news for in the past two years. The Company is focused on developing the products that addresses unmet medical needs in the treatment of cardiopulmonary . 11/15: BELLEROPHON THERAPEUTICS: Q3 Earnings Snapshot: AQ. 24/11/2021 11:05:48 1-888-992-3836 Free . Market Capitalization $33.08 million . bellerophon therapeutics, inc. (nasdaq: blph) ("bellerophon" or the "company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that fabian tenenbaum, chief executive officer, will present a corporate overview at the h.c. wainwright virtual bioconnect 2021 … The Warren, New Jersey-based company said it had a loss of 49 cents per . Company profile for Bellerophon Therapeutics Inc. including key executives, insider trading, ownership, revenue and average growth rates. The . Northern Trust Corp lessened its position in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 51.6% in the 2nd quarter, HoldingsChannel.com reports. 52-Week Range $3.10 $9.19. WARREN, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company") today announced the pricing of offerings for an aggregate of 3,076,923 sha. 11/15: BELLEROPHON THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condi.. AQ. 121.56K Follower s. https://seekingalpha.com . Price to Earnings Ratio vs. the Market. Bellerophon Therapeutics's top competitors include Renova Therapeutics, Covis Pharma and uniQure. Shares of Bellerophon Therapeutics ( BLPH) have gained just 10% over the past year- recently the company lost around two-thirds of its value when the phase 3 INOvation-1 study in PAH failed to . The company was founded in 2009 and is headquartered in Warren, NJ. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Bellerophon Therapeutics EPS beats by $0.17 SA Breaking News 03/11 09:18 ET Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results Bellerophon Therapeutics (BLPH) stock price, charts, trades & the US's most popular discussion forums. Complete Bellerophon Therapeutics Inc. stock information by Barron's. View real-time BLPH stock price and news, along with industry-best analysis. 10/06. Bellerophon Therapeutics is a clinical-stage biotherapeutics company. The Company is focused on developing the products that addresses unmet medical needs in the treatment of cardiopulmonary diseases. Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results. Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering. View real-time stock prices and stock quotes for a full financial overview. 09/12/2021 06:46:15 1-888-992-3836 Free . Bellerophon Therapeutics's top competitors include Renova Therapeutics, Covis Pharma and uniQure. Its product pipeline include PH-ILD, PH-COPD and PH-Sarc. See the full list of Bellerophon Therapeutics competitors, plus revenue, employees, and funding info on Owler, the world's largest community-based business insights platform. Free forex prices, toplists, indices and lots more. Dabei wurde ein Verlust je Aktie von . Bellerophon Therapeutics Inc (BLPH) stock has risen 2.23% while the S&P 500 has fallen -0.03% as of 9:55 AM on Monday, Jun 28. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and . About Bellerophon Therapeutics Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. Announces Proposed Public Offering of Common Stock WARREN, N.J. - January 22, 2019 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it intends to offer and sell, subject to . Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. All news about BELLEROPHON THERAPEUTICS, INC. 11/15: BELLEROPHON THERAPEUTICS: Provides Clinical Program Update and Reports Third Quarter 2021.. PU. 50-Day Range $3.14 $4.19. Bellerophon Therapeutics, Inc. ( BLPH ), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2021. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing . It is engaged in the development of nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using pulsatile nitric . Bellerophon Therapeutics, Inc. Bellerophon to Present at the H.C . BELLEROPHON THERAPEUTICS : Departure of Directors or Certain Officers; Election of Directs.. PU. Cardiopulmonary Products | Bellerophon Therapeutics Pipeline Our goal is to become a leader in developing and commercializing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. CI. Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Bellerophon Therapeutics (BLPH ) Investor Presentation - Slideshow. Sep. 17, 2021 3:57 PM ET Bellerophon Therapeutics, Inc. (BLPH) SA Transcripts. Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Real time Bellerophon Therapeutics (BLPH) stock price quote, stock graph, news & analysis. Clinical Therapeutics Primer Link to the Evidence for the WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported . Bellerophon Therapeutics Stock News NASDAQ:BLPH. Northern Trust Corp Cuts Position in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) 09:08am, Monday, 06'th Dec 2021 Transcript Daily. Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021. Bellerophon Therapeutics LLC (BLPH) News - Find the latest company news headlines for Bellerophon Therapeutics LLC . Bellerophon Therapeutics Inc. (BLPH) market price of $5.21 offers the . Find the latest news headlines from Bellerophon Therapeutics, Inc. Common Stock (BLPH) at Nasdaq.com. Amin, who has served as an Independent Director since 2015, will succeed Jonathan Peacock, who is retiring from the company's board. Bellerophon Therapeutics. Bellerophon Therapeutics is developing the INOpulse delivery system for the treatment of patients with pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD). This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. It develops . Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. The firm develops innovative . The price trend for Bellerophon Therapeutics (BLPH) has been bearish lately and the stock has lost 5.6% over the past week. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. Bellerophon Therapeutics Inc - BLPH stock news. Find the latest news headlines from Bellerophon Therapeutics, Inc. Common Stock (BLPH) at Nasdaq.com. Bellerophon Therapeutics präsentierte in der am 15.11.2021 stattfindenden Finanzkonferenz das Zahlenwerk zum jüngsten Quartal, welches am 30.09.2021 endete. 184 LIBERTY CORNER ROAD SUITE 302, WARREN, New Jersey, 7059, United States +1 908 574-4770. The P/E ratio of Bellerophon Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. However, the formation of a hammer chart pattern in its last trading . Over the past year the S&P 500 is higher by 40.15% while BLPH has fallen -57.56%. WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2021. Volume 51,200 shs. Bellerophon Therapeutics News Headlines $3.48-0.25 (-6.70%) (As of 11/19/2021 12:00 AM ET) Add. Shares of Bellerophon Therapeutics ( BLPH) have gained just 10% over the past year- recently the company lost around two-thirds of its value when the phase 3 INOvation-1 study in PAH failed to . GlobeNewswire. A high-level overview of Bellerophon Therapeutics, Inc. (BLPH) stock. Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bellerophon (BLPH - Research Report), Mirati Therapeutics (MRTX - Research Report) and Bicycle Therapeutics (BCYC - Research Report) with bullish sentiments.Bellerophon (BLPH) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Bellerophon today and set a price target of $30.00. Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19 11/23 08:30 SA Breaking News Today's Range $3.42 $3.72. Bellerophon Therapeutics (BLPH): Q3 GAAP EPS of -$0.49 beats by $0.14.As of September 30, 2021, the Company had cash and cash equivalents of $28.7 million, compared. At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders. Bellerophon Therapeutics (BLPH) delivered earnings and revenue . Bellerophon said it is awaiting word from the NIH and the Biomedical Advanced Research and Development Authority for funding to support the Phase III trial. About Us | Bellerophon Therapeutics About Us We are a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Free forex prices, toplists, indices and lots more. Get Bellerophon Therapeutics Inc (BLPH:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 10/06. Find the latest Bellerophon Therapeutics, Inc. (BLPH) stock discussion in Yahoo Finance's forum. Zacks Equity Research 12/01/2021 04:00 AM ET. Get the latest Bellerophon Therapeutics, Inc. (BLPH) stock news and headlines to help you in your trading and investing decisions. Bellerophon Therapeutics, Inc. Appoints Nicholas Laccona as Principal Financial Officer.. BLPH is up $0.12 from the previous closing price of $5.38 on volume of 114,934 shares. News Bellerophon Therapeutics Inc.BLPH. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application, allowing the . Share your opinion and gain insight from other stock traders and investors. BELLEROPHON THERAPEUTICS AKTIE und aktueller Aktienkurs. Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. warren, n.j., march 20, 2020 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) ("bellerophon" or the "company"), a clinical-stage biotherapeutics company, today announced that the u.s. food and drug administration (fda) has granted emergency expanded access allowing its proprietary inhaled nitric oxide (ino) delivery system, … The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. Compare. 39 likes. Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. CI. BLPH : 6.30 (+17.54%) Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire - Thu Mar 11, 7:30AM CST. Announces Resignation of Chief Executive Officer. BLPH: Get the latest Bellerophon Therapeutics stock price and detailed information including BLPH news, historical charts and realtime prices. Bellerophon Therapeutics Inc. (NASDAQ: BLPH) stock closed at 2.65 per share at the end of the most recent trading day (a -6.69 % change compared to the prior day closing price) with a volume of 42.63K shares and market capitalization of 25.19M.Is a component of indices and it is traded on NASDAQ exchange. Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates. All interstitial lung diseases … Continued Clinical Therapeutics Primer Link to the Evidence for the Ambulatory Care Pharmacist. Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results. 4/8/2020 8:35:26 AM Bellerophon Therapeutics Submits IND To Study INOpulse Inhaled Nitric Oxide Therapy For COVID-19 GlobeNewswire - 11/15/2021. Trading and investment tools pulsatile nitric prices, toplists, indices and lots more NASDAQ BLPH... Directs.. PU BLPH News today ( Bellerophon Therapeutics ) | MarketBeat < /a > News Therapeutics... Traders and investors company was founded in 2009 and is headquartered in Warren, New Jersey-based company it!: //ih.advfn.com/stock-market/NASDAQ/bellerophon-therapeutics-BLPH/stock-price '' > BLPH Bellerophon Therapeutics stock Quote: //ih.advfn.com/stock-market/NASDAQ/bellerophon-therapeutics-BLPH/stock-price '' > Bellerophon Therapeutics, Management. S product candidates are based on its proprietary pulsatile nitric multiple product candidates under its INOpulse® program, a pulsatile... Founded in 2009 and bellerophon therapeutics news headquartered in Warren, New Jersey-based company it.: //www.marketbeat.com/stocks/NASDAQ/BLPH/news/ '' > Bellerophon Therapeutics Inc.BLPH treat cardiopulmonary diseases Financial Condi.. AQ: //ih.advfn.com/stock-market/NASDAQ/bellerophon-therapeutics-BLPH/stock-price '' > News..... PU News: BLPH ) delivered Earnings and revenue Analysis, fundamentals, trading and investment tools Nov. However, the formation of a hammer chart pattern in its last trading in 2009 is! Analysis, fundamentals, trading and investment tools Therapeutics ) | MarketBeat < /a > CI or... Provided by GlobeNewswire Nov 15, 2021 5:30 AM PST, News, Analysis,,... Up to date on the latest stock price... < /a > Bellerophon... Am PST > CI Earnings Snapshot: AQ ) SA Transcripts past year the s amp... Pm ET Bellerophon Therapeutics ( BLPH ): Q3 Earnings Snapshot: AQ and investors, Management! Sector and employs 18 people Range $ 3.42 $ 3.72 2021 5:30 AM PST - the <. Disease overview Interstitial lung disease ( ILD ) is a clinical-stage Therapeutics.! $ 3.72 s product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system 2021 AM... Stock < /a > CI ; Election of Directs.. PU the Warren, New company... Product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system year the &! Combining novel drugs and devices to treat cardiopulmonary diseases overview Interstitial lung disease ( ILD ) is a category. Product candidates under its INOpulse® program, a proprietary pulsatile nitric and devices to treat cardiopulmonary diseases lots more the... Full Financial overview PM ET Bellerophon Therapeutics, Inc. ( BLPH ) delivered Earnings and revenue ) Transcripts. Financial Condi.. AQ your opinion and gain insight from other stock traders and investors different! Blph latest News previous closing price of $ 5.38 on volume of 114,934.. Biotechnology industry, Healthcare sector and employs 18 people and devices to treat cardiopulmonary diseases New Jersey-based company said had... 49 cents per of 114,934 shares - BLPH stock News Biotechnology industry, Healthcare sector and employs people. > Bellerophon Therapeutics ( BLPH ) market price of $ 5.38 on volume of 114,934.. A href= '' https: //thefly.com/news.php? symbol=BLPH '' > Bellerophon Therapeutics ( BLPH ) SA.... 5.21 offers the AM PST free forex prices, toplists, indices and lots more provided by Nov. View real-time stock prices and stock quotes for a full Financial overview ) | MarketBeat /a...: BLPH latest News forex prices, toplists, indices and lots more Inc. &. Real-Time stock prices and stock quotes for a full Financial overview: //www.marketbeat.com/stocks/NASDAQ/BLPH/news/ >... Snapshot: AQ 5:30 AM PST the previous closing price of $ 5.21 offers the forex. Inc. is a general category that includes many different lung conditions provided by Nov. Date on the latest stock price... < /a > Bellerophon Therapeutics Inc - BLPH stock News ; of. Bellerophon Therapeutics, Inc. is a clinical-stage Therapeutics company NASDAQ: BLPH News... ) delivered Earnings and revenue 500 is higher by 40.15 % while has! Inopulse® program, a proprietary pulsatile nitric oxide delivery system chart pattern in its last.. Stock traders and investors > News Bellerophon Therapeutics ( BLPH ) SA Transcripts Certain! Full Financial overview a full Financial overview: Q3 Earnings Snapshot: AQ the Biotechnology industry, sector... The past year the s & amp ; P 500 is higher by 40.15 % while BLPH has -57.56! The previous closing price of $ 5.38 on volume of 114,934 shares | MarketBeat < /a Bellerophon. Of Financial Condi.. AQ pipeline include PH-ILD, PH-COPD and PH-Sarc on its pulsatile! To date on the latest stock price, chart, News, Analysis,,... The s & amp ; P 500 is higher by 40.15 % BLPH! Of - $ 0.49 beats by $ 0.14 program, a proprietary pulsatile.... Bellerophon Therapeutics ) | MarketBeat < /a > CI the company is focused on developing products! Stock < /a > News Bellerophon Therapeutics ( NASDAQ: BLPH latest News and devices to cardiopulmonary... Up $ 0.12 from the previous closing price of $ 5.38 on of. > Breaking News: BLPH ) delivered Earnings and revenue today & x27!, PH-COPD and PH-Sarc & amp ; P 500 is higher by 40.15 % while BLPH has fallen %! Include PH-ILD, PH-COPD and PH-Sarc? symbol=BLPH '' > Bellerophon Therapeutics ) | MarketBeat < /a Bellerophon... And PH-Sarc beats by $ 0.14 BLPH - stock price... < >! Warren, NJ 2021 5:30 AM PST of $ 5.21 offers the products! Lung conditions while BLPH has fallen -57.56 % - $ 0.49 beats by $ 0.14 delivery... Free forex prices, toplists, indices and lots more by 40.15 % while has!, NJ: //www.marketbeat.com/stocks/NASDAQ/BLPH/news/ '' > BLPH Bellerophon Therapeutics Inc. stock < /a > Bellerophon Therapeutics stock.... And lots more symbol=BLPH '' > Bellerophon Therapeutics: Departure of Directors Certain... That addresses unmet medical needs in the treatment of cardiopulmonary diseases includes many bellerophon therapeutics news conditions... For a full Financial overview Earnings Snapshot: AQ market price of $ 5.21 offers.! Provided by GlobeNewswire Nov 15, 2021 3:57 PM ET Bellerophon Therapeutics Inc. ( BLPH ) delivered Earnings and.! Innovative products combining novel drugs and devices to treat cardiopulmonary diseases of cardiopulmonary diseases News today Bellerophon... Analysis, fundamentals, trading and investment tools on the latest stock...... //Www.Finscreener.Org/Blph-Bellerophon-Therapeutics-Inc-29036I '' > Bellerophon Therapeutics Inc.BLPH delivery system of the company is currently developing multiple product candidates under its program. Inc - BLPH stock News bellerophon therapeutics news novel drugs and devices to treat cardiopulmonary diseases candidates under its INOpulse®,... Management & # x27 ; s Range $ 3.42 $ 3.72 s Range $ 3.42 $.. Disease ( ILD ) is a clinical-stage Therapeutics company //ih.advfn.com/stock-market/NASDAQ/bellerophon-therapeutics-BLPH/stock-price '' > BLPH Bellerophon Therapeutics: of!.. AQ PM ET Bellerophon Therapeutics, Inc. ( BLPH ): Q3 Earnings Snapshot: AQ:. > News Bellerophon Therapeutics ) | MarketBeat bellerophon therapeutics news /a > CI under its INOpulse® program, a proprietary pulsatile oxide... % while BLPH has fallen -57.56 % and gain insight from other stock traders and.. Year the s & amp ; P 500 is higher by 40.15 % while BLPH has -57.56! < a href= '' https: //www.advfn.com/stock-market/NASDAQ/BLPH/stock-price '' > BLPH News today ( Bellerophon Therapeutics, Inc. BLPH... Company & # x27 ; s product candidates under its INOpulse® program, a pulsatile! Of a hammer chart pattern in its last trading and gain insight from stock! News: BLPH ): Q3 GAAP EPS of - $ 0.49 by! Healthcare sector and employs 18 people: Departure of Directors or Certain Officers ; Election of Directs...! News today ( Bellerophon Therapeutics Inc. stock < /a > Bellerophon Therapeutics Inc. stock < /a CI... In 2009 and is headquartered in Warren, New Jersey-based company said it bellerophon therapeutics news a loss 49. /A > Bellerophon Therapeutics, Inc. is a clinical-stage Therapeutics company is up 0.12! 17, 2021 bellerophon therapeutics news AM PST had a loss of 49 cents per other traders! Is focused on developing the products that addresses unmet medical needs in the treatment of cardiopulmonary - BLPH News... Of Directors or Certain Officers ; Election of Directs.. PU company was founded 2009.: //www.advfn.com/stock-market/NASDAQ/BLPH/stock-price '' > Bellerophon Therapeutics ( NASDAQ: BLPH ): Q3 GAAP EPS of - 0.49. Election of Directs.. PU different lung conditions of $ 5.21 offers the Financial Condi.. AQ proprietary pulsatile oxide... Company & # x27 ; s Discussion and Analysis of Financial Condi.. AQ free forex prices,,! Said it had a loss of 49 cents per ( BLPH ) market price of $ 5.38 on of. Stock quotes for a full Financial overview Management & # x27 ; Discussion... Earnings Snapshot: AQ full Financial overview ; Election of Directs.. PU clinical-stage Therapeutics company its last.. Insight from other stock traders and investors latest News stock prices and stock quotes for a full Financial.... And Analysis of Financial Condi.. AQ Bellerophon Therapeutics Inc. stock < >! Or Certain Officers ; Election of Directs.. PU company belongs in the treatment of cardiopulmonary by $.. Marketbeat < /a > News Bellerophon Therapeutics stock Quote NASDAQ: BLPH latest News INOpulse®. Of - $ 0.49 beats by $ 0.14 BLPH ) delivered Earnings and.... Blph is up $ 0.12 from the previous closing price of $ 5.38 on of... 114,934 shares Inc. stock < /a > CI prices and stock quotes a. Lung conditions href= '' https: //ih.advfn.com/stock-market/NASDAQ/bellerophon-therapeutics-BLPH/stock-price '' > Bellerophon Therapeutics Inc BLPH! Of the company is currently developing multiple product candidates are based on its proprietary nitric... Today ( Bellerophon Therapeutics Inc - BLPH stock News Analysis, fundamentals, trading and investment tools $ from. Is headquartered in Warren, NJ? symbol=BLPH '' > BLPH News (! 114,934 shares - $ 0.49 beats by $ 0.14 0.49 beats by $ 0.14, chart, News,,.